BTIG Raises Tempus AI PT to $85, Maintains Buy Rating

BTIG Raises Tempus AI PT to $85, Maintains Buy Rating

BTIG has recently raised its price target for Tempus AI, Inc. (TEM) to $85, while maintaining a Buy rating for the stock. The upgrade comes amidst a series of strategic partnerships and expansion efforts by Tempus AI in the healthcare sector, particularly in oncology and neuroscience [1].

Tempus AI, leveraging its AI platforms — Lens and Next — has been rapidly expanding its partnerships. Key collaborations include a multi-year agreement with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine to analyze genomic data in Alzheimer’s research. Additionally, Tempus has partnered with the Institute for Follicular Lymphoma Innovation to create a real-world data library, and with Boehringer Ingelheim to advance cancer pipeline development [1].

BTIG analysts cited Tempus AI's strong pipeline, expanding partnerships, and growing revenue as the primary reasons for the price target increase. The company's strategic collaborations with leading institutions and pharmaceutical companies are expected to drive growth and enhance its market position in precision medicine [1].

Despite the positive outlook, Tempus AI has faced regulatory scrutiny and legal challenges in recent months, which have impacted its stock price. Allegations of inflated contract values and unethical billing practices have led to a class-action lawsuit and a significant drop in stock value [2]. The company's earnings report revealed a net income of -$43M and a pretax profit margin of -29.2%, indicating financial instability and operational hurdles [2].

BTIG's analysts remain optimistic about Tempus AI's long-term potential, acknowledging the challenges posed by the legal issues. They believe that addressing these concerns and maintaining transparency will be crucial for the company's recovery and future growth [2].

References:
[1] https://www.nasdaq.com/articles/strategic-partnerships-power-tempus-ais-healthcare-expansion
[2] https://stockstotrade.com/news/tempus-ai-inc-tem-news-2025_08_19/